Abstract
SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction. Here we show that a particularly vulnerable population with neurologic manifestations of COVID-19 harbor an influx of inflammatory cytokines within the cerebrospinal fluid in the absence of viral neuro-invasion. The majority of these inflammatory mediators are driven by type 2 interferon and are known to induce neuronal injury in other disease models. Levels of matrix metalloproteinase-10 within the spinal fluid correlate with the degree of neurologic dysfunction. Furthermore, this neuroinflammatory process persists weeks following convalescence from the acute respiratory infection. These prolonged neurologic sequelae following a systemic cytokine release syndrome lead to long-term neurocognitive dysfunction with a wide range of phenotypes.
Competing Interest Statement
A.B. is an inventor on United States Provisional Patent Application No.: 62/258,044 Modulating Permeability of The Blood Cerebrospinal Fluid Barrier. A.B. is an unpaid member of the Scientific Advisory Board of EVREN Technologies. Other authors declare no competing interests.
Funding Statement
This work was supported by NCI P30 CA008748 (Cancer Center Support Grant); and The Pew Charitable Trusts GC241069, The Damon Runyon Cancer Research Foundation GC240764, The Pershing Square Sohn Cancer Research Alliance GC239280, The Baker Family Foundation, and The W.M. Keck Foundation (all to A.B.). J.R. is supported by The American Brain Tumor Association Basic Research Fellowship, The Terri Brodeur Breast Cancer Foundation Fellowship, and The Druckenmiller Center for Lung Cancer Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical statement. This study was conducted according to the principles expressed in the Declaration of Helsinki. Ethical approval for COVID-19-relared research was obtained from MSKCC Institutional Review Board (IRB) under protocol #20-006. Collection and use of clinical samples were approved by MSKCC IRB #06-107, #12-245, #13-039, and #18-505. Only clinical samples collected in excess of those needed for diagnostic and therapeutic procedures were used for research. All participants provided written informed consent for sample and clinical data collection and subsequent analyses.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- ACE2
- angiotensin-converting enzyme 2
- AIE
- autoimmune encephalitis
- CAR T
- chimeric antigen receptor T cell
- CCL
- C-C motif chemokine ligand
- CRP
- C-reactive protein
- CSF
- cerebrospinal fluid
- CXCL
- C-X-C motif chemokine ligand
- DRS
- disability rating scale
- EEG
- electroencephalography
- ELISA
- enzyme-linked immunosorbent assay
- GRDA
- generalized rhythmic delta activity
- ICAN
- Immune Effector Cell-Associated Neurotoxicity Syndrome
- IFN
- interferon
- IL
- interleukin
- KPS
- Karnofsky performance status
- LP
- lumbar puncture
- MRI
- magnetic resonance imaging
- MMP-10
- matrix metallopeptidase- 10
- MCP2
- monocyte chemoattractant protein-2
- PCR
- polymerase chain reaction
- PDR
- posterior dominant rhythm.
